TN2009000095A1 - Thiazole pyrazolopyrimidines as crf1 receptor antagonists - Google Patents

Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Info

Publication number: TN2009000095A1
Authority: TN; Tunisia
Prior art keywords: receptor antagonists; crf1 receptor; pyrazolopyrimidines; thiazole; thiazole pyrazolopyrimidines
Prior art date: 2006-09-20

Application number

TN2009000095A

Other languages

English (en)

Inventor

Zhaogen Chen

Chafiq Hamdouchi Hamdouchi

Erik James Hembre

Philip Arthur Hipskind

Jason Kenneth Myers

Takako Takakuwa

James Lee Toth

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2009-03-19

Publication date

2010-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000095(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-19 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2010-08-19 Publication of TN2009000095A1 publication Critical patent/TN2009000095A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Anesthesiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TN2009000095A 2006-09-20 2009-03-19 Thiazole pyrazolopyrimidines as crf1 receptor antagonists TN2009000095A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82626406P	2006-09-20	2006-09-20
PCT/US2007/078605 WO2008036579A1 (fr)	2006-09-20	2007-09-17	Thiazole pyrazolopyrimidines convenant comme antagonistes du récepteur du crf1

Publications (1)

Publication Number	Publication Date
TN2009000095A1 true TN2009000095A1 (en)	2010-08-19

Family

ID=38924802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000095A TN2009000095A1 (en)	2006-09-20	2009-03-19	Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Country Status (33)

Country	Link
US (1)	US8030304B2 (fr)
EP (1)	EP2094709B1 (fr)
JP (1)	JP5161226B2 (fr)
KR (1)	KR101088239B1 (fr)
CN (1)	CN101516887B (fr)
AR (1)	AR062886A1 (fr)
AT (1)	ATE481405T1 (fr)
AU (1)	AU2007297421B2 (fr)
BR (1)	BRPI0717023B8 (fr)
CA (1)	CA2663511C (fr)
CL (1)	CL2007002693A1 (fr)
CR (1)	CR10682A (fr)
CY (1)	CY1110854T1 (fr)
DE (1)	DE602007009305D1 (fr)
DK (1)	DK2094709T3 (fr)
EA (1)	EA015179B1 (fr)
ES (1)	ES2350282T3 (fr)
HR (1)	HRP20100516T1 (fr)
IL (1)	IL197614A (fr)
MA (1)	MA30798B1 (fr)
MX (1)	MX2009003125A (fr)
MY (1)	MY146388A (fr)
NO (1)	NO20091489L (fr)
NZ (1)	NZ575572A (fr)
PE (1)	PE20081377A1 (fr)
PL (1)	PL2094709T3 (fr)
PT (1)	PT2094709E (fr)
RS (1)	RS51545B (fr)
SI (1)	SI2094709T1 (fr)
TN (1)	TN2009000095A1 (fr)
TW (1)	TWI402269B (fr)
UA (1)	UA96458C2 (fr)
WO (1)	WO2008036579A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2350079B1 (fr) *	2008-10-02	2012-11-14	Eli Lilly & Company	Composés de thiazolylpyrazolopyrimidine à usage d'intermédiaires de synthèse et procédés de synthèse associés
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
MX389004B (es)	2014-01-21	2025-03-20	Neurocrine Biosciences Inc	Antagonistas de receptor del factor de liberación de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congénita.
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
US11077108B2 (en)	2016-09-07	2021-08-03	The Regents Of The University Of California	Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition
CN110997667A (zh) *	2017-08-14	2020-04-10	云杉生物科学公司	促肾上腺皮质激素释放因子受体拮抗剂
CA3064464A1 (fr)	2017-08-14	2019-02-21	Spruce Biosciences, Inc.	Antagonistes du recepteur du facteur de liberation de la corticotropine
CA3098562A1 (fr) *	2018-04-27	2019-10-31	Spruce Biosciences, Inc.	Methodes de traitement de tumeurs des vertiges surrenaliens des testicules et des ovaires
CN109134481B (zh) *	2018-08-07	2021-05-14	中山大学	一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物
EP3984523B1 (fr)	2018-12-07	2025-09-03	Neurocrine Biosciences, Inc.	Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
KR20220052927A (ko) *	2019-07-19	2022-04-28	스프루스 바이오사이언시스 인코포레이티드	선천성 부신 증식증의 치료 방법
EP4034111A1 (fr)	2019-09-27	2022-08-03	Neurocrine Biosciences, Inc.	Antagonistes du récepteur crf et méthodes d'utilisation
AR120649A1 (es) *	2019-12-04	2022-03-09	Neurocrine Biosciences Inc	Antagonistas del receptor de crf y métodos de uso
GR1010096B (el) *	2020-07-02	2021-10-08	Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε,	Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
IL300478A (en) *	2020-08-12	2023-04-01	Spruce Biosciences Inc	Methods and preparations for the treatment of polycystic ovary syndrome
JP2023540223A (ja)	2020-08-26	2023-09-22	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよび使用方法
CA3211644A1 (fr)	2021-03-19	2022-09-22	Christine FERRARA-COOK	Antagoniste du recepteur du sous-type 2 de la melanocortine (mc2r) pour le traitement d'une maladie
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
CA3235958A1 (fr) *	2021-11-19	2023-05-25	Spruce Biosciences, Inc.	Composition cristalline de tildacerfont et ses methodes d'utilisation et de preparation
WO2023163945A1 (fr) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Traitement de l'hyperplasie surrénale congénitale et du syndrome des ovaires polykystiques
WO2025188842A1 (fr) *	2024-03-08	2025-09-12	Spruce Biosciences, Inc.	Dispersion solide amorphe de formulations de tildacerfont

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL176526B1 (pl)	1992-12-17	1999-06-30	Pfizer	Pirolopirymidyny jako związki o działaniu antagonistów czynnika uwalniającego kortykotropinę
EE04282B1 (et) *	1996-02-07	2004-04-15	Janssen Pharmaceutica N.V.	Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon
HU228962B1 (en)	1996-07-24	2013-07-29	Bristol Myers Squibb Pharma Co	Azolo triazines, pharmaceutical compositions containing them and use of the compounds
BR9710544A (pt) *	1996-07-24	1999-08-17	Du Pont Pharm Co	M-todo de tratamento composto e composi-Æo farmac-utica
NZ333302A (en)	1996-08-28	2000-08-25	Pfizer	Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor
EP1040831A3 (fr) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
AU4203500A (en)	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
CN1377355A (zh)	1999-09-30	2002-10-30	纽罗杰有限公司	氨基取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
EP1368094B1 (fr) *	2001-03-13	2007-02-28	Bristol-Myers Squibb Pharma Company	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo- 1,5-a\|-1,3,5-triazine, ses enantiomeres et sels pharmaceutiquement acceptables en tant que ligands du recepteur de la corticoliberine
JP4926720B2 (ja) *	2003-12-22	2012-05-09	スミスクラインビーチャム（コーク）リミテッド	Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法

2007
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active Expired - Fee Related
- 2007-09-17 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2007-09-17 CA CA2663511A patent/CA2663511C/fr active Active
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/en unknown
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/fr active Application Filing
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 EP EP07842582A patent/EP2094709B1/fr active Active
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
2010
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown

Also Published As

Publication number	Publication date
CN101516887B (zh)	2011-11-02
MX2009003125A (es)	2009-05-28
RS51545B (en)	2011-06-30
WO2008036579A1 (fr)	2008-03-27
NZ575572A (en)	2011-10-28
DE602007009305D1 (de)	2010-10-28
EA200970303A1 (ru)	2009-10-30
CY1110854T1 (el)	2015-06-10
IL197614A (en)	2012-10-31
BRPI0717023B8 (pt)	2021-05-25
UA96458C2 (ru)	2011-11-10
TWI402269B (zh)	2013-07-21
SI2094709T1 (sl)	2011-01-31
ATE481405T1 (de)	2010-10-15
HK1132505A1 (en)	2010-02-26
NO20091489L (no)	2009-04-16
BRPI0717023B1 (pt)	2019-11-19
EA015179B1 (ru)	2011-06-30
CN101516887A (zh)	2009-08-26
US8030304B2 (en)	2011-10-04
KR101088239B1 (ko)	2011-11-30
HRP20100516T1 (hr)	2010-10-31
US20100222339A1 (en)	2010-09-02
EP2094709A1 (fr)	2009-09-02
PT2094709E (pt)	2010-10-04
TW200821312A (en)	2008-05-16
CR10682A (es)	2009-08-13
PL2094709T3 (pl)	2011-02-28
DK2094709T3 (da)	2010-12-06
CA2663511C (fr)	2012-12-04
PE20081377A1 (es)	2008-09-18
KR20090052366A (ko)	2009-05-25
MA30798B1 (fr)	2009-10-01
AR062886A1 (es)	2008-12-10
IL197614A0 (en)	2009-12-24
BRPI0717023A2 (pt)	2014-03-11
CL2007002693A1 (es)	2008-04-18
MY146388A (en)	2012-08-15
ES2350282T3 (es)	2011-01-20
JP2010504344A (ja)	2010-02-12
AU2007297421B2 (en)	2012-03-08
AU2007297421A1 (en)	2008-03-27
JP5161226B2 (ja)	2013-03-13
EP2094709B1 (fr)	2010-09-15
CA2663511A1 (fr)	2008-03-27

Publication	Publication Date	Title
TN2009000095A1 (en)	2010-08-19	Thiazole pyrazolopyrimidines as crf1 receptor antagonists
MX2009003098A (es)	2009-04-01	Compuestos de tiofen pirazolopirimidina.
EA200702044A1 (ru)	2008-02-28	Имидазопиридазиновые соединения
GB0625648D0 (en)	2007-01-31	Compounds
MX2010013020A (es)	2011-03-21	Metodos y composiciones para trastornos del sueño y otros trastornos.
DK1951729T3 (da)	2014-10-06	Oxygenbundne pyrimidinderivater
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA200602062A1 (ru)	2007-04-27	Амидосоединения и их применение в качестве фармацевтических средств
SG170828A1 (en)	2011-05-30	Deazapurines useful as inhibitors of janus kinases
ZA201100526B (en)	2012-04-25	Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
WO2008045564A3 (fr)	2008-05-29	Composés de carboxamide et leur utilisation
MX2009010127A (es)	2009-11-05	Compuestos utiles como inhibidores de janus cinasas.
GEP20135927B (en)	2013-10-10	1-benzyl-3-hydroxymethylindaz-ole derivatives and usage thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DE602007007934D1 (en)	2010-09-02	Imidazoazephinonverbindungen
WO2006138589A3 (fr)	2009-04-16	Ligands de recepteur opioide
WO2005094798A3 (fr)	2006-04-13	Compositions pharmaceutiques a base d'anticholinergiques et d'antagonistes du recepteur ccr2